Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · D

Aspargo Labs, Inc.

SEC Filing

Filed Mar 28, 2022Accepted Mar 28, 2022, 11:19 AM EDTCIK 1805092Accession 0001753926-22-000348
Share

Company context

Aspargo is a commercial stage specialty pharmaceutical and med-tech company focused on designing, developing and marketing proprietary, oral liquid suspension formulations of leading oral solid dose prescription (Rx) and over-the-counter (OTC) medications dispensed through “smart”, digitally connected, container closure drug delivery systems and associated mobile apps.

Recent company filings

  1. RW filingJul 29, 2026
  2. S-1/A filingJan 10, 2025
  3. S-1 filingJan 10, 2025
  4. DRS/A filingSep 13, 2024
  5. DRS/A filingAug 7, 2024

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗